Search

Your search keyword '"Tran, Ben"' showing total 850 results
Start Over Author "Tran, Ben"
850 results on '"Tran, Ben"'

102. Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)

Author

Berry, Sneha, Giraldo, Nicolas, Nguyen, Peter, Green, Benjamin, Xu, Haiying, Ogurtsova, Aleksandra, Soni, Abha, Succaria, Farah, Wang, Daphne, Roberts, Charles, Stein, Julie, Engle, Elizabeth, Pardoll, Drew, Anders, Robert, Cottrell, Tricia, Taube, Janis M., Tran, Ben, Voskoboynik, Mark, Kuo, James, Bang, Yung-Lue, Chung, Hyun-Cheo, Ahn, Myung-Ju, Kim, Sang-We, Perera, Ayesh, Freeman, Daniel, Achour, Ikbel, Faggioni, Raffaella, Xiao, Feng, Ferte, Charles, Lemech, Charlotte, Meric-Bernstam, Funda, Werner, Theresa, Hodi, Stephen, Messersmith, Wells, Lewis, Nancy, Talluto, Craig, Dostalek, Mirek, Tao, Aiyang, McWhirter, Sarah, Trujillo, Damian, Luke, Jason, Xu, Chunxiao, BoMarelli, Qi, Jin, Qin, Guozhong, Yu, Huakui, Jenkins, Molly, Lo, Kin-Ming, Halle, Joern-Peter, Lan, Yan, Taylor, Matthew, Vogelzang, Nicholas, Cohn, Allen, Stepan, Daniel, Shumaker, Robert, Dutcus, Corina, Guo, Matthew, Schmidt, Emmett, Rasco, Drew, Brose, Marcia, Vogelzang, Nicholas, Di Simone, Christopher, Jain, Sharad, Richards, Donald, Encarnacion, Carlos, Rasco, Drew, Shumaker, Robert, Dutcus, Corina, Stepan, Daniel, Guo, Matthew, Schmidt, Emmett, Taylor, Matthew, Vogelzang, Nicholas, Encarnacion, Carlos, Cohn, Allen, Di Simone, Christopher, Rasco, Drew, Richards, Donald, Taylor, Matthew, Dutcus, Corina, Stepan, Daniel, Shumaker, Robert, Guo, Matthew, Schmidt, Emmett, Mier, James, An, Jeongshin, Yang, Yeun-yeoul, Lee, Won-Hee, Yang, Jinho, Kim, Jong-kyu, Kim, Hyun Goo, Paek, Se Hyun, Lee, Jun Woo, Woo, Joohyun, Kim, Jong Bin, Kwon, Hyungju, Lim, Woosung, Paik, Nam Sun, Kim, Yoon-Keun, Moon, Byung-In, Janku, Filip, Tan, David, Martin-Liberal, Juan, Takahashi, Shunji, Geva, Ravit, Gucalp, Ayca, Chen, Xueying, Subramanian, Kulandayan, Mataraza, Jennifer, Wheler, Jennifer, and Bedard, Philippe

Published
2019
Full Text
View/download PDF

103. Trial in progress: PREPARE—Exploring the activity of pseudoephedrine in treating retrograde ejaculation following retroperitoneal lymph node dissection (RPLND) in survivors of testicular cancer (TC).

Author

Conduit, Ciara, primary, Lewin, Jeremy Howard, additional, Sim, Ie-Wen, additional, Dhillon, Haryana M., additional, Hong, Wei, additional, Hutchinson, Amanda, additional, Ahmad, Gulfam, additional, Lawrentschuk, Nathan, additional, Thomas, Benjamin, additional, Leonard, Matt, additional, and Tran, Ben, additional

Published
2023
Full Text
View/download PDF

104. Phase 2 study of the efficacy and safety of erdafitinib in patients (pts) with bacillus Calmette-Guérin (BCG)-unresponsive, high-risk non–muscle-invasive bladder cancer (HR-NMIBC) with FGFR3/2 alterations (alt) in THOR-2: Cohort 2 interim analysis results.

Author

Catto, James W.F., primary, Tran, Ben, additional, Master, Viraj A., additional, Roupret, Morgan, additional, Pignot, Geraldine, additional, Tubaro, Andrea, additional, Shimizu, Nobuaki, additional, Vasdev, Nikhil, additional, Gschwend, Jürgen E., additional, Loriot, Yohann, additional, Nishiyama, Hiroyuki, additional, Redorta, Joan, additional, Daneshmand, Siamak, additional, Miura, Yuji, additional, Naini, Vahid, additional, Crow, Lauren, additional, Triantos, Spyros, additional, Baig, Mahadi, additional, and Steinberg, Gary D., additional

Published
2023
Full Text
View/download PDF

105. Phase 1/2a study of AZD5305, a novel poly(adenosine diphosphate ribose) polymerase (PARP) 1-selective inhibitor in combination with new hormonal agents (NHAs) in patients (pts) with metastatic prostate cancer (mPC).

Author

Azad, Arun, primary, Voskoboynik, Mark, additional, Palma dos Reis, Ana Filipa, additional, Joshua, Anthony M., additional, Weickhardt, Andrew James, additional, Jones, Robert J., additional, Rescigno, Pasquale, additional, Tran, Ben, additional, Kennedy, Caroline, additional, Linardopoulos, Spiros, additional, Moorthy, Ganesh, additional, Zhou, TJ, additional, Brown, Jessica S, additional, Lukacs, Edit, additional, Francis, Richard, additional, and Hudson, Andrew, additional

Published
2023
Full Text
View/download PDF

107. Heterogeneity of canonical prostate cancer markers across lesions in metastatic castration-resistant prostate cancer.

Author

Trigos, Anna S., primary, Pasam, Anupama, additional, Inderjeeth, Andrisha-Jade, additional, Cain, Lachlan D., additional, Weng, Sirui, additional, Gupta, Vinita, additional, Sable, Beate, additional, Paweletz, Katherine L., additional, Bailis, Julie M., additional, Zhang, Yangyi, additional, Feng, Yuzhou, additional, Anton, Angelyn, additional, Tran, Ben, additional, Mitchell, Catherine, additional, and Sandhu, Shahneen, additional

Published
2023
Full Text
View/download PDF

108. Efficacy of systemic therapy following [177Lu] Lu-PSMA in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Author

Kostos, Louise Kathleen, primary, Lai, William Yu Ching, additional, Lambroglou, Peter, additional, Medhurst, Elizabeth, additional, Buteau, James Patrick, additional, Sandhu, Shahneen, additional, Tran, Ben, additional, Spain, Lavinia Anne, additional, Conduit, Ciara, additional, Wallace, Roslyn, additional, Alipour, Ramin, additional, Akhurst, Timothy J., additional, Kong, Grace, additional, Cardin, Anthony, additional, Saghebi, Javad, additional, Ravi Kumar, Aravind, additional, Hofman, Michael S, additional, and Azad, Arun, additional

Published
2023
Full Text
View/download PDF

109. Trial in progress: PRESTIGE—Primary retroperitoneal lymph node dissection (RPLND) for clinical stage II (CSII) testicular germ cell tumour (TGCT) and its impact on health-related quality of life (HRQoL) compared to chemotherapy or radiotherapy.

Author

Conduit, Ciara, primary, Lewin, Jeremy Howard, additional, Liow, Elizabeth Chien Hern, additional, Dhillon, Haryana M., additional, Hong, Wei, additional, De Abreu Lourenço, Richard, additional, Lawrentschuk, Nathan, additional, Thomas, Benjamin, additional, Grimison, Peter S., additional, Ahmadi, Nariman, additional, Sengupta, Shomik, additional, and Tran, Ben, additional

Published
2023
Full Text
View/download PDF

110. A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition inBRAFV600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study

Author

Tan, Lavinia, primary, Tran, Ben, additional, Tie, Jeanne, additional, Markman, Ben, additional, Ananda, Sumi, additional, Tebbutt, Niall C., additional, Michael, Michael, additional, Link, Emma, additional, Wong, Stephen Q., additional, Chandrashekar, Sushma, additional, Guinto, Jerick, additional, Ritchie, David, additional, Koldej, Rachel, additional, Solomon, Benjamin J., additional, McArthur, Grant A., additional, Hicks, Rodney J., additional, Gibbs, Peter, additional, Dawson, Sarah-Jane, additional, and Desai, Jayesh, additional

Published
2023
Full Text
View/download PDF

113. Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor-targeted agents matter?

Author

Pereira-Salgado, Amanda, primary, Anton, Angelyn, additional, Franchini, Fanny, additional, Mahar, Robert K., additional, Kwan, Edmond M., additional, Wong, Shirley, additional, Shapiro, Julia, additional, Weickhardt, Andrew, additional, Azad, Arun A., additional, Spain, Lavinia, additional, Gunjur, Ashray, additional, Torres, Javier, additional, Parente, Phillip, additional, Parnis, Francis, additional, Goh, Jeffrey, additional, Steer, Christopher, additional, Brown, Stephen, additional, Gibbs, Peter, additional, Tran, Ben, additional, and IJzerman, Maarten, additional

Published
2022
Full Text
View/download PDF

114. Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database Consortium

Author

Takemura, Kosuke, primary, Navani, Vishal, additional, Ernst, Matthew S., additional, Wells, J. Connor, additional, Meza, Luis, additional, Pal, Sumanta K., additional, Lee, Jae-Lyun, additional, Li, Haoran, additional, Agarwal, Neeraj, additional, Alva, Ajjai S., additional, Hansen, Aaron R., additional, Basappa, Naveen S., additional, Szabados, Bernadett, additional, Powles, Thomas, additional, Tran, Ben, additional, Hocking, Christopher M., additional, Beuselinck, Benoit, additional, Yuasa, Takeshi, additional, Choueiri, Toni K., additional, and Heng, Daniel Y. C., additional

Published
2022
Full Text
View/download PDF

115. Additional file 2 of 'Nothing to lose and the possibility of gaining': a qualitative study on the feasibility and acceptability of registry-based randomised controlled trials among cancer patients and clinicians

Author

Prang, Khic-Houy, Karanatsios, Bill, Zhang, Angela, Verbunt, Ebony, Wong, Hui-li, Wong, Vanessa, Gately, Lucy, Tran, Ben, Gibbs, Peter, and Kelaher, Margaret

Abstract

Additional file 2: Appendix 2. Inclusion and exclusion criteria for cancer patients across the three trials.

Published
2023
Full Text
View/download PDF

117. Prostate‐specific membrane antigen positron emission tomography‐computed tomography use prior to systemic therapy in metastatic castration‐resistant prostate cancer

Author

Kelly, Richard, primary, Jensen, Andrew, additional, Karunaratna, Nathasha, additional, Wong, Shirley, additional, Shapiro, Julia, additional, Weickhardt, Andrew, additional, Parente, Phillip, additional, Azad, Arun A., additional, Uccellini, Anthony, additional, Torres, Javier, additional, Parnis, Francis, additional, Goh, Jeffrey, additional, Kwan, Edmond M., additional, Brown, Stephen, additional, Steer, Christopher, additional, Warren, Mark, additional, Gibbs, Peter, additional, Tran, Ben, additional, and Anton, Angelyn, additional

Published
2022
Full Text
View/download PDF

118. 277 Development of a robust manufacturing process for AB-1015, an integrated circuit T cell (ICT) product, using targeted, CRISPR integration of transgenes by electroporation (CITE) editing

Author

Chang, Alice, primary, Phillips, Sophia, additional, Lee, Max, additional, Huang, Elizabeth, additional, Anand, Navneet, additional, Ko, Hayden, additional, Tran, Stella, additional, Rios, Lindsay, additional, Dai, Rory, additional, Nguyen, Anton, additional, Vasudevan, Anu, additional, Steinfeld, Rona Harari, additional, Polyak, Dina, additional, Fuhriman, Jessica, additional, Yun, Hongruo, additional, Feng, Jun, additional, Wang, Haixia, additional, Tran, Ben, additional, Smith, Jenessa, additional, and Sirichoke, Tim, additional

Published
2022
Full Text
View/download PDF

119. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial

Author

Buteau, James P, primary, Martin, Andrew J, additional, Emmett, Louise, additional, Iravani, Amir, additional, Sandhu, Shahneen, additional, Joshua, Anthony M, additional, Francis, Roslyn J, additional, Zhang, Alison Y, additional, Scott, Andrew M, additional, Lee, Sze-Ting, additional, Azad, Arun A, additional, McJannett, Margaret M, additional, Stockler, Martin R, additional, Williams, Scott G, additional, Davis, Ian D, additional, Hofman, Michael S, additional, Akhurst, Tim, additional, Alipour, Ramin, additional, Banks, Patricia, additional, Beaulieu, Alexis, additional, Buteau, James P, additional, Chua, Wei, additional, Dhiantravan, Nattakorn, additional, Ford, Kate, additional, Gedye, Craig, additional, Goh, Jeffrey C, additional, Guminski, Alex, additional, Hamid, Anis, additional, Haskali, Mohammad B, additional, Hicks, Rodney J, additional, Hsiao, Edward, additional, Kirkwood, Ian D, additional, Kong, Grace, additional, Kwan, Edmond M, additional, Langford, Ailsa, additional, Lawrence, Nicola, additional, Lewin, Jeremy, additional, Lin, Peter, additional, McDonald, William, additional, Moodie, Kate, additional, Murphy, Declan G, additional, Ng, Siobhan, additional, Pattison, David A, additional, Pokorski, Izabella, additional, Ramdave, Shakher, additional, Ravi Kumar, Aravind S, additional, Redfern, Andrew D, additional, Rutherford, Natalie K, additional, Saghebi, Javad, additional, Spain, Lavinia, additional, Subramaniam, Shalini, additional, Tan, Thean Hsiang, additional, Thang, Sue Ping, additional, Tran, Ben, additional, Wallace, Roslyn, additional, Weickhardt, Andrew, additional, and Yip, Sonia, additional

Published
2022
Full Text
View/download PDF

121. 558 CTX130 allogeneic CRISPR-Cas9–engineered chimeric antigen receptor (CAR) T cells in patients with advanced clear cell renal cell carcinoma: Results from the phase 1 COBALT-RCC study

Author

Pal, Sumanta, primary, Tran, Ben, additional, Haanen, John, additional, Hurwitz, Michael, additional, Sacher, Adrian, additional, Agarwal, Neeraj, additional, Tannir, Nizar, additional, Budde, Elizabeth, additional, Harrison, Simon, additional, Klobuch, Sebastian, additional, Patel, Sagar, additional, Dequeant, Mary Lee, additional, Karsten, Verena, additional, Cohen, Kaitlyn, additional, Gurary, Ellen, additional, Dar, Henia, additional, Ma, Anna, additional, Sharma, Anjali, additional, and Srour, Samer, additional

Published
2022
Full Text
View/download PDF

122. Role for a Web-Based Intervention to Alleviate Distress in People With Newly Diagnosed Testicular Cancer: Mixed Methods Study

Author

Conduit, Ciara, primary, Guo, Christina, additional, Smith, Allan B, additional, Rincones, Orlando, additional, Baenziger, Olivia, additional, Thomas, Benjamin, additional, Goad, Jeremy, additional, Lenaghan, Dan, additional, Lawrentschuk, Nathan, additional, Wong, Lih-Ming, additional, Corcoran, Niall M, additional, Ross, Margaret, additional, Gibbs, Peter, additional, O'Haire, Sophie, additional, Anton, Angelyn, additional, Liow, Elizabeth, additional, Lewin, Jeremy, additional, and Tran, Ben, additional

Published
2022
Full Text
View/download PDF

139. Leveraging Comprehensive Cancer Registry Data to Enable a Broad Range of Research, Audit and Patient Support Activities

Author

Lee, Belinda, primary, Gately, Lucy, additional, Lok, Sheau Wen, additional, Tran, Ben, additional, Lee, Margaret, additional, Wong, Rachel, additional, Markman, Ben, additional, Dunn, Kate, additional, Wong, Vanessa, additional, Loft, Matthew, additional, Jalili, Azim, additional, Anton, Angelyn, additional, To, Richard, additional, Andrews, Miles, additional, and Gibbs, Peter, additional

Published
2022
Full Text
View/download PDF

140. A meta-analysis of clinicopathologic features that predict necrosis or fibrosis at post-chemotherapy retroperitoneal lymph node dissection in individuals receiving treatment for non-seminoma germ cell tumours

Author

Conduit, Ciara, primary, Hong, Wei, additional, Martin, Felicity, additional, Thomas, Benjamin, additional, Lawrentschuk, Nathan, additional, Goad, Jeremy, additional, Grimison, Peter, additional, Ahmadi, Nariman, additional, Tran, Ben, additional, and Lewin, Jeremy, additional

Published
2022
Full Text
View/download PDF

142. Abstract CT016: MEDI5752, a novel PD-1/CTLA-4 bispecific checkpoint inhibitor for advanced solid tumors: First-in-human study

Author

Tran, Ben, primary, Voskoboynik, Mark, additional, Kim, Sang-We, additional, Lemech, Charlotte, additional, Carcereny, Enric, additional, Rha, Sun Young, additional, Ahn, Myung-Ju, additional, Felip, Enriqueta, additional, Lee, Ki H., additional, Alvarez, Eduardo C., additional, Yang, James Chih-Hsin, additional, Ascierto, Paolo A., additional, Pulla, Mariano P., additional, Freeman, Dan, additional, Song, Xuyang, additional, Gainer, Shelby D., additional, Mitchell, Patrick, additional, Achour, Ikbel, additional, Subramaniam, Deepa S., additional, and Im, Seock-Ah, additional

Published
2022
Full Text
View/download PDF

143. Circulating tumour cells (CTCs) and PSMA PET correlates in the phase I PRINCE trial of 177Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC).

Author

Hamid, Anis, primary, Hofman, Michael S, additional, Bressel, Mathias, additional, Emmett, Louise, additional, Joshua, Anthony M., additional, Spain, Lavinia Anne, additional, Horvath, Lisa, additional, Crumbaker, Megan, additional, Pasam, Anupama, additional, Callahan, Jason, additional, Tubbs, Alisa, additional, Fernandez, Luisa, additional, Wenstrup, Richard J., additional, Kong, Grace, additional, Lewin, Jeremy Howard, additional, Tran, Ben, additional, Azad, Arun, additional, Schonhoft, Joseph D., additional, Hicks, Rodney J., additional, and Sandhu, Shahneen, additional

Published
2022
Full Text
View/download PDF

144. Safety and clinical activity of MEDI5752, a PD-1/CTLA-4 bispecific checkpoint inhibitor, as monotherapy in patients (pts) with advanced renal cell carcinoma (RCC): Preliminary results from an FTIH trial.

Author

Albiges, Laurence, primary, Medina Rodriguez, Laura, additional, Kim, Sang-We, additional, Im, Seock-Ah, additional, Carcereny, Enric, additional, Rha, Sun Young, additional, Tran, Ben, additional, Oliveira, Julio, additional, Maroto-Rey, Pablo, additional, Su, Wu-Chou, additional, Voskoboynik, Mark, additional, Rodriguez-Vida, Alejo, additional, Costa, Luis, additional, Ascierto, Paolo Antonio, additional, Insa Molla, Maria Amelia, additional, Wang, Yi, additional, Gainer, Shelby D., additional, Subramaniam, Deepa S, additional, and Voss, Martin H, additional

Published
2022
Full Text
View/download PDF

146. Peritoneal carcinosis in male germ cell tumor patients:a registry study compiled by the German Testicular Cancer Study Group (GTCSG)

Author

Seidel, Christoph, Hentrich, Marcus, Zschäbitz, Stefanie, Paffenholz, Pia, Heidenreich, Axel, Nestler, Tim, Tran, Ben, Fischer, Stefanie, Daugaard, Gedske, Ochsenreither, Sebastian, Brito, Margarida, Zengerling, Friedemann, Schwab, Constantin, Bokemeyer, Carsten, Oing, Christoph, Seidel, Christoph, Hentrich, Marcus, Zschäbitz, Stefanie, Paffenholz, Pia, Heidenreich, Axel, Nestler, Tim, Tran, Ben, Fischer, Stefanie, Daugaard, Gedske, Ochsenreither, Sebastian, Brito, Margarida, Zengerling, Friedemann, Schwab, Constantin, Bokemeyer, Carsten, and Oing, Christoph

Abstract

Purpose: To report on the clinical characteristics, outcome, and frequency of peritoneal carcinosis (PC) in patients with advanced germ cell tumors (GCT), a multicenter registry analysis was carried out. Methods: A multicenter registry analysis was conducted by the German Testicular Cancer Study Group (GTCSG) with international collaborators. Data was collected and analyzed retrospectively. Patients were eligible for inclusion if PC was diagnosed either by radiologic or histopathologic finding during the course of disease. Descriptive and explorative statistical analysis was carried out with cancer-specific survival (CSS) as primary study endpoint. Results: Collaborators from ten GCT expert centers identified 28 GCT (0.77%) patients with PC after screening approximately 3767 GCT patient files and one case was contributed from a cancer registry request. Patients were diagnosed from 1997 to 2019 at a median age of 37 years (interquartile range, 13). Two patients (7%) presented with stage I and 27 patients (93%) with synchronous metastatic disease at first diagnosis. The primary histology was seminoma in seven (27%) and non-seminoma in 21 patients (72%). PC was detected after a median of 15.3 months from primary diagnosis (range 0–177) and two consecutive treatment lines (range 0–5), respectively. The median CSS from the time of detection of PC was 10.5 months (95%Confidence Interval 0.47–1.30) associated with an overall 2-year CSS rate of 30%. Conclusion: PC represents a rare tumor manifestation in GCT patients and was primarily associated with the occurrence of advanced cisplatin-refractory disease conferring to a dismal prognosis.

Published
2022

148. TSTEM-like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical models.

Author

Meyran, Deborah, Zhu, Joe Jiang, Butler, Jeanne, Tantalo, Daniela, MacDonald, Sean, Nguyen, Thu Ngoc, Wang, Minyu, Thio, Niko, D'Souza, Criselle, Qin, Vicky Mengfei, Slaney, Clare, Harrison, Aaron, Sek, Kevin, Petrone, Pasquale, Thia, Kevin, Giuffrida, Lauren, Scott, Andrew M., Terry, Rachael L., Tran, Ben, and Desai, Jayesh

Abstract

Patients who receive chimeric antigen receptor (CAR)–T cells that are enriched in memory T cells exhibit better disease control as a result of increased expansion and persistence of the CAR-T cells. Human memory T cells include stem-like CD8+ memory T cell progenitors that can become either functional stem-like T (TSTEM) cells or dysfunctional T progenitor exhausted (TPEX) cells. To that end, we demonstrated that TSTEM cells were less abundant in infused CAR-T cell products in a phase 1 clinical trial testing Lewis Y-CAR-T cells (NCT03851146), and the infused CAR-T cells displayed poor persistence in patients. To address this issue, we developed a production protocol to generate TSTEM-like CAR-T cells enriched for expression of genes in cell replication pathways. Compared with conventional CAR-T cells, TSTEM-like CAR-T cells had enhanced proliferative capacity and increased cytokine secretion after CAR stimulation, including after chronic CAR stimulation in vitro. These responses were dependent on the presence of CD4+ T cells during TSTEM-like CAR-T cell production. Adoptive transfer of TSTEM-like CAR-T cells induced better control of established tumors and resistance to tumor rechallenge in preclinical models. These more favorable outcomes were associated with increased persistence of TSTEM-like CAR-T cells and an increased memory T cell pool. Last, TSTEM-like CAR-T cells and anti–programmed cell death protein 1 (PD-1) treatment eradicated established tumors, and this was associated with increased tumor-infiltrating CD8+CAR+ T cells producing interferon-γ. In conclusion, our CAR-T cell protocol generated TSTEM-like CAR-T cells with enhanced therapeutic efficacy, resulting in increased proliferative capacity and persistence in vivo. Tuning up CAR-T cells: A major goal for improving chimeric antigen receptor (CAR)–T cell therapy is to ensure that the CAR-T cell products infused into patients with cancer function optimally. However, standard manufacturing protocols do not enrich for cellular phenotypes associated with enhanced function. To address this, Meyran et al. developed a protocol that generated TSTEM-like CAR-T cells, which exhibit features of stem-like T cells. As compared with conventionally produced CAR-T cells, TSTEM-like CAR-T cells were more proliferative and produced more cytokines after CAR stimulation in vitro; they also exhibited superior control of tumor burden in vivo. Together, these results support the implementation of production strategies to generate TSTEM-like CAR T cells for clinical use. —CM [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

149. Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database Consortium.

Author

Kosuke Takemura, Navani, Vishal, Ernst, Matthew S., Wells, J. Connor, Meza, Luis, Pal, Sumanta K., Jae-Lyun Lee, Li, Haoran, Agarwal, Neeraj, Alva, Ajjai S., Hansen, Aaron R., Basappa, Naveen S., Szabados, Bernadett, Powles, Thomas, Tran, Ben, Hocking, Christopher M., Beuselinck, Benoit, Takeshi Yuasa, Choueiri, Toni K., and Heng, Daniel Y. C.

Subjects
RENAL cell carcinoma, PROTEIN-tyrosine kinase inhibitors, DATABASES, VASCULAR endothelial growth factors
Abstract

Purpose: Clinical trials have demonstrated higher complete response rates in the immuno-oncologye based combination arms than in the tyrosine kinase inhibitor arms in patients with metastatic renal cell carcinoma. We aimed to characterize real-world patients who experienced complete response to the contemporary first-line therapies. Materials and Methods: Using the International Metastatic Renal Cell Carcinoma Database Consortium, response-evaluable patients who received frontline immuno-oncologye based combination therapy or tyrosine kinase inhibitor monotherapy were analyzed. Baseline characteristics of patients and post-landmark overall survival were compared based on best overall response, as per RECIST 1.1. Results: A total of 52 (4.6%) of 1,126 and 223 (3.0%) of 7,557 patients experienced complete response to immuno-oncologye based and tyrosine kinase inhibitor therapies, respectively (P [ .005). An adjusted odds ratio for complete response achieved by immuno-oncologye based combination therapy (vs tyrosine kinase inhibitor monotherapy) was 1.56 (95% CI 1.11-2.17; P [ .009). Among patients who experienced complete response, the immuno-oncologye based cohort had a higher proportion of noneclear cell histology (15.9% and 4.7%; P [ .016), sarcomatoid dedifferentiation (29.8% and 13.5%; P [ .014), and multiple sites of metastases (80.4% and 50.0%; P < .001) than the tyrosine kinase inhibitor cohort. Complete response was independently associated with post-landmark overall survival benefit in both the immuno-oncologye based and tyrosine kinase inhibitor cohorts, giving respective adjusted hazard ratios of 0.17 (95% CI 0.04-0.72; P [ .016) and 0.28 (95% CI 0.21-0.38; P < .001). Conclusions: The complete response rate was not as high in the real-world population as in the clinical trial population. Among those who experienced complete response, several adverse clinicopathological features were more frequently observed in the immuno-oncologye based cohort than in the tyrosine kinase inhibitor cohort. Complete response was an indicator of favorable overall survival. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results